English
中文简体
中文繁体
Company
Overview
Board of Directors
Partnering
Technology
Glycan-specific Conjugation
Alphatecan
Bispecific Antibody
Subcutaneous Formulation
Single-domain Antibody
Publications
Pipeline
Overview
Envafolimab(KN035)
KN026
JSKN003
JSKN016
JSKN033
KN046
KN019
Investors
Information Disclosure
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
News
Press Release
Media Report
Career
Corporate Culture
Job Opportunities
Contact Us
Company
Overview
Board of Directors
Partnering
Technology
Glycan-specific Conjugation
Alphatecan
Bispecific Antibody
Subcutaneous Formulation
Single-domain Antibody
Publications
Pipeline
Overview
Envafolimab(KN035)
KN026
JSKN003
JSKN016
JSKN033
KN046
KN019
Investors
Information Disclosure
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
News
Press Release
Media Report
Career
Corporate Culture
Job Opportunities
Contact Us
English
中文简体
中文繁体
Investors
Information Disclosure
Listing Documents
Financial Reports
Announcements & Circulars
Company Presentation
ESG Reports
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
Announcements & Circulars
The announcement begins in December 2019
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2021
2021-03-04
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2021
2021-02-05
VOLUNTARY ANNOUNCEMENT – ABSTRACTS ON CLINICAL DATA FROM PHASE II CLINICAL STUDY OF KN046 IN PATIENTS WITH ADVANCED NSCLC AND PRELIMINARY RESULTS OF KN046 IN PATIENTS WITH RARE THORACIC TUMORS FOR PRESENTATION AT WCLC 2020
2021-01-13
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2020
2021-01-08
VOLUNTARY ANNOUNCEMENT - INCLUSION OF THE SHARES OF THE COMPANY IN THE HONG KONG STOCK CONNECT LIST UNDER THE SHENZHEN-HONG KONG STOCK CONNECT
2020-12-28
VOLUNTARY ANNOUNCEMENT - THE COMBINATION THERAPY OF KN026 AND KN046 WAS GRANTED ORPHAN DRUG DESIGNATION BY THE U.S. FDA
2020-12-23
WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES
2020-12-23
VOLUNTARY ANNOUNCEMENT - BLA ACCEPTED BY THE NMPA FOR KN035 IN THE TREATMENT OF MSI-H/DMMR SOLID TUMORS
2020-12-21
CHANGE OF JOINT COMPANY SECRETARY AND AUTHORIZED REPRESENTATIVE AND TERMINATION OF THE ENGAGEMENT OF THE CHIEF FINANCIAL OFFICER AND THE BOARD SECRETARY
2020-12-07
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2020
2020-12-04
18
19
20
21
22
23
24
PREV
21/27
NEXT